JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ROBSON, J. M.
Right arrow Articles by ANSARI, M. Y.
Right arrow Search for Related Content
PubMed
Right arrow Articles by ROBSON, J. M.
Right arrow Articles by ANSARI, M. Y.
Journal of Pharmacology And Experimental Therapeutics, Vol. 79, Issue 4, 340-345, 1943
Copyright © 1943 by American Society for Pharmacology and Experimental Therapeutics

THE FATE OF D.B.E. (agragr DI-(p-ETHOXYPHENYL)beta-PHENYL BROMO-ETHYLENE) IN THE BODY

J. M. ROBSON 1 and M. Y. ANSARI 1

1 From the Department of Pharmacology, University of Edinburgh

D.B.E. was administered to ovariectomized mice by stomach tube. Twenty-four hours later, less than 50% of the dose could be recovered from the body, but after that the elimination became slower and was almost completed in 3 weeks.

The highest concentration of the substance was found in the body fat from which it was more slowly eliminated than from the rest of the body. Only 5-10% of the dose given could be recovered from the excreta. Most of this was present in the faeces.

In vitro experiments suggest that the liver does not play an important part in the inactivation of the substance.

The mode of action of D.B.E. is discussed and it is suggested that it may be suitable for the treatment of conditions in which prolonged oestrogenic action is required.

Submitted on August 13, 1943




This article has been cited by other articles:


Home page
 Endocr. Rev.Home page
V. C. Jordan and M. Morrow
Tamoxifen, Raloxifene, and the Prevention of Breast Cancer
Endocr. Rev., June 1, 1999; 20(3): 253 - 278.
[Abstract] [Full Text]

Home page
 Arch DermatolHome page
A. L. WELSH
USE OF SYNTHETIC ESTROGENIC SUBSTANCE CHLOROTRIANISENE (TACE) IN TREATMENT OF ACNE
Arch Dermatol, April 1, 1954; 69(4): 418 - 427.
[Abstract] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1943 by the American Society for Pharmacology and Experimental Therapeutics.